What we do Rubicon Research Limited is an integrated pharmaceutical company specializing in specialty products, drug-device combinations, and complex generics targeting regulated markets, primarily the US. |
Founded in 1,999 |
Market share A leading niche player with a diverse portfolio of 83 approved products and strong US market presence through Validus acquisition. |
Problem solved Develops innovative and specialty pharmaceutical products to address complex treatment needs in regulated markets, enhancing patient care. |
Top clients or who we serve Serves US pharmaceutical market with branded and non-branded prescription drugs; key customers include wholesalers, pharmacies, and healthcare providers (B2B & B2C). |
Key management Pratibha Pilgaonkar (MD) with 25 years’ pharma R&D experience; Parag Sancheti (CEO) with 12 years leadership in pharma strategy and management. |
Our journey and innovations Founded in 1999; transitioned from contract services to specialty products; acquired key facilities and Validus in the US; pioneered nasal spray drug-device combinations. |
Where we operate Primarily operates in India with manufacturing and R&D facilities; marketing and sales in the US; exports also to other global markets. |
Top products or what we offer Range includes oral solids, liquids, topical ointments, nasal spray drug-device combinations; flagship brands include Raldesy®, Equetro®, Lopressor® OS. |
Top brands Raldesy®, Equetro®, Lopressor® OS - all without FDA-approved generic alternatives and strong US market positions. |
Raw materials needed Active Pharmaceutical Ingredients (API), excipients, specialty chemical compounds for formulation of complex generics and drug-device products. |
Raw materials supplier Sourced globally from specialized API and chemical manufacturers; specifics confidential. |
Recurring vs cyclical contribution Revenue is primarily recurring from specialty product sales in regulated markets with steady demand and growing pipeline. |
Our industry position Strong niche player with expanding specialty portfolio and USFDA-approved manufacturing, commanding a distinctive presence in complex generics. |
Financial highlights FY25 revenue ₹12,843 million; net profit ₹1,344 million; FY26 9M revenue ₹12,400 million; net profit ₹1,700 million; growth driven by specialty products. |
Geographical revenue split FY24-25: USA contributes over 98% revenue; India and other regions together less than 3% of total revenue. |
Order book - |
Whats driving growth Robust R&D pipeline, increasing FDA approvals, specialty product focus, recent acquisitions and expansion in manufacturing capacities. |
Our future plans Ramp up Pithampur facility by mid-2026, sustain R&D spends at ~10% revenue, expand US sales and specialty product portfolio. |
Our green promise Committed to sustainable manufacturing and ethical practices; specific ESG initiatives not detailed. |
Our people and values Over 190 R&D professionals and experienced leadership promoting innovation, quality, and responsible growth. |
Key challenges ahead Managing manufacturing scale-up, regulatory approvals, competitive US market pressures, and reliance on outsourced manufacturing during growth phase. |
Interesting facts Achieved simultaneous USFDA approvals before inspections; specialty products contribute over 30% gross margin; successful IPO in 2025. |
Risks and strategy Risks include regulatory delays and market competition; strategy focuses on R&D-driven innovation, manufacturing expansion, and niche product leadership. |
